Search
Displaying all 3 results
Naxitamab
go.drugbank.com/drugs/DB15965
ApprovedInvestigational
Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside. Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - ...
High risk, refractory Neuroblastomas of the bone or bone marrow
go.drugbank.com/conditions/DBCOND0134732Drugs: NaxitamabHigh risk, relapsed Neuroblastomas of the bone or bone marrow
go.drugbank.com/conditions/DBCOND0134730Drugs: Naxitamab